Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses

Journal of Immunotherapy

Volumn 31, Issue 8, 2008, Pages 704-713

  Linnebacher, Michael ^a   Maletzki, Claudia ^a   Emmrich, Jörg ^a   Kreikemeyer, Bernd ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Immune response; Immunotherapy; Mouse model; Pancreatic cancer

Indexed keywords

BACTERIUM LYSATE; GAMMA INTERFERON; LYSINE; STREPTOCOCCUS PYOGENES LYSATE; UNCLASSIFIED DRUG; CANCER VACCINE; CELL EXTRACT; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; BACTERIOPHAGE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE; TUMOR IMMUNITY; ACTIVE IMMUNIZATION; ANIMAL; BACTERIUM; BLOOD; C57BL MOUSE; IMMUNOLOGY; METHODOLOGY; PANCREAS TUMOR; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIA; CANCER VACCINES; CELL EXTRACTS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; STREPTOCOCCUS PYOGENES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 59849119193     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181829f62     Document Type: Article

References (31)

1. Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. Bioessays. 2006;28:84-94.
2. Suzuki S, Shinohara N, Harabayashi T, et al. Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol. 2002;7:289-293.
3. Van Mellaert L, Barbe S, Anne J. Clostridium spores as anti-tumour agents. Trends Microbiol. 2006;14:190-196.
4. Yazawa K, Fujimori M, Nakamura T, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat. 2001 ;66:165-170.
5. Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA. 2004;101:15172-15177.
6. Zhao M, Yang M, Li XM, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA. 2005;18:755-760.
7. Maletzki C, Linnebacher M, Kreikemeyer B, et al. Pancreatic cancer regression by intratumoral injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut. 2008;57:483-491.
8. Ishii KJ, Kawakami K, Gursel I, et al. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clin Cancer Res. 2003;9:6516-6522.
9. Melief CJ, Toes RE, Medema JP, et al. Strategies for immunotherapy of cancer. Adv Immunol. 2000;75:235-282.
10. Pastan I, Kreitman RJ. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev. 1998;31:53-88.
11. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci. 2003;8:e115-e127.
12. Cho YJ, Ahn BY, Song ES, et al. Bacterial DNA containing methylated CpG motifs retains immunostimulatory activity in synergy with modified lipopolysaccharides. Microbiol Immunol. 2007;51:211-222.
13. Yoshikawa T, Tsuburaya A, Kobayashi O, et al. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma. Hepatogastroenterology. 2003;50:2259-2263.
14. Ahmed SU, Okamoto M, Oshikawa T, et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother (1997). 2004;27:432-441.
15. Oshikawa T, Okamoto M, Tano T, et al. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent. J Immunother (1997). 2006;29:143-150.
16. Homma S, Sagawa Y, Komita H, et al. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation. Cancer Immunol Immunother. 2007;56:1265-1274.
17. Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6:559-565.
18. Yang WS, Park SO, Yoon AR, et al. Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol Cancer Ther. 2006;5:1610-1619.
19. Nelson D, Schuch R, Chahales P, et al. PlyC: a multimeric bacteriophage lysin. Proc Natl Acad Sci USA. 2006;103:10765-10770.
20. Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother (1997). 2001;24:502-510.
21. Shan BE, Hao JS, Li QX, et al. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol. 2006;3:47-52.
22. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64:529-564.
23. Simons MP, Nauseef WM, Griffith TS. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunol Res. 2007;39:79-93.
24. Chong H, Hutchinson G, Hart IR, et al. Expression of costimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther. 1996;7:1771-1779.
25. Turnquist HR, Kohlgraf KG, McIlhaney MM, et al. Tapasin decreases immune responsiveness to a model tumor antigen. J Clin Immunol. 2004;24:462-470.
26. Ganss R, Ryschich E, Klar E, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62:1462-1470.
27. Breitbach CJ, Paterson JM, Lemay CG, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther. 2007;15:1686-1693.
28. Eisold S, Schmidt J, Ryschich E, et al. Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma. Pancreas. 2007;35:63-72.
29. Jäger E, Jäger D, Knuth A. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev. 1999;18:143-150.
30. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006;12:214-219.
31. Ullrich E, Bonmort M, Mignot G, et al. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res. 2007;67:851-853.